videoSlug

VideoSlug_VideoQuery

slug

VideoPageContentQuery

content

videos

query VideoSlug_VideoQuery(
  $videoSlug: String!
) {
  ...VideoPageContentQuery_1X4EH4
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment LatestVideos_Videos on Query {
  videos(first: 5, upcoming: false, order: {field: liveTime, direction: DESC}) {
    edges {
      node {
        id
        title
        lang
        pageUrl
        liveTime
        isLive
        companies {
          name
          squareLogoUrl
          id
        }
      }
    }
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment VideoPageContentQuery_1X4EH4 on Query {
  content(slug: $videoSlug, type: [VIDEO, WEBCAST]) {
    __typename
    id
    title
    slug
    lang
    htmlBody
    isPremium
    companies {
      viewerIsFollowing
      id
      name
      pageUrl
      defaultInstrument {
        id
        isin
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    createdAt
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    ... on Video {
      imgUrl
      videoEmbedUrl(location: "inderes")
      audioEmbedUrl
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ... on Webcast {
      imgUrl
      videoEmbedUrl(location: "inderes")
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
  }
  ...LatestVideos_Videos
}


type

__typename

title

lang

htmlBody

isPremium

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

first

order

upcoming

edges

Flerie

Meet InDex Pharmaceuticals’ external advisor– Daniel Lundberg presenting the company’s go-to-market strategy in the US with the phase III product cobitolimod for the treatment of moderate to...

Meet InDex Pharmaceuticals&rsquo; external advisor&ndash; Daniel Lundberg presenting the company&rsquo;s go-to-market strategy in the US with the phase III product cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis. The event takes place on the 9th of June &ndash; at 15:00 CET. InDex&nbsp;Pharmaceuticals revealed its strategy for the US market in connection with their Capital Markets Day &ndash; on March 14th, 2022. The company expects to self-commercialize the product in the very important US market with the expected product launch in 2027. Market characteristics 2020:
<ul>
<li>Global market ulcerative colitis&nbsp; &ndash; 7.5bn. USD</li>
<li>Advanced therapies ulcerative colitis &ndash; 6.4 bn. USD</li>
<li>Moderate to severe left-sided ulcerative colitis &ndash; 3.5 bn. USD</li>
</ul>
The US market is 2/3 of the global market, and the global market CAGR is 6% per annum. Dan Lundberg has extensive experience in the pharmaceutical industry and the gastrointestinal (GI) market, with 13 product launches on his CV. InDex Pharmaceuticals is a Swedish pharmaceutical development company seeking to improve the lives of patients suffering from immunological diseases. Our mission is to develop effective and safe drugs for diseases with significant medical needs. Our current focus is ulcerative colitis, a chronic and debilitating inflammation of the large intestine that affects patients of all ages, though it is most commonly diagnosed when patients are 15-30 years old. Cobitolimod is part of InDex Pharmaceuticals&rsquo; patent-protected technology platform of TLR9-agonists, the so-called DNA-based ImmunoModulatory Sequences (DIMS). With their immunomodulatory effects, meaning they help modify the body&rsquo;s immune response, DIMS substances can potentially treat multiple immunological diseases. InDex Pharmaceuticals was founded in 2000 and is located at Karolinska Institutet Science Park in Stockholm. InDex has a strong investor base with Linc AB, HBM Healthcare Investments, 4th AP Fund, and Handelsbanken fonder among its top shareholders.
Disclaimer: HC Andersen Capital receives payment from Index Pharmaceuticals for a DigitalIR/Corporate Visibility agreement.

HC Andersen Capital

Index Pharmaceuticals – Commercial strategy - 09.06.2022

Orion

Orion as an Investment | Life Science Night Dec. 9, 2025

AKTIER MED FRIIS - UGE 50 2025

Novo Nordisk

Bavarian Nordic

Gubra

A.P. Møller - Mærsk

Pandora

FLSmidth & Co.

Nilfisk Holding

GN Store Nord

Flügger Group

HCA Morgenbørs 12/12 - Positive futures og fokus på FLSmidth og fedme aktier

Verve Group

A sit-down with CEO Remco Westermann

Aiforia Technologies

Aiforia as an Investment | Life Science Night Dec  9, 2025

Recent videos